Sumitovant Biopharma acquires UROV for_$16.25/sh_cash—a_96%_premium to today’s closing price: https://www.prnewswire.com/news-releases/sumitovant-biopharma-and-urovant-sciences-announce-sumitovants-acquisition-of-remaining-stake-in-urovant-301172414.html Sumitovant already owned a 72% equity stake in UROV. The nominal deal value (for the full company) is $681M.